WEI HU to Neoplasms, Glandular and Epithelial
This is a "connection" page, showing publications WEI HU has written about Neoplasms, Glandular and Epithelial.
Connection Strength
0.797
-
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther. 2012 Sep; 13(11):1034-41.
Score: 0.298
-
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48.
Score: 0.084
-
Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett. 2013 Apr 28; 330(2):123-9.
Score: 0.074
-
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Oct; 127(1):70-4.
Score: 0.074
-
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16; 366(7):610-8.
Score: 0.072
-
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer. 2010 Dec; 1(6):277-90.
Score: 0.066
-
Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1717-32.
Score: 0.049
-
Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets. 2006 Feb; 10(1):77-85.
Score: 0.047
-
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9.
Score: 0.016
-
Prognostic biomarkers in ovarian cancer. Cancer Biomark. 2010-2011; 8(4-5):231-51.
Score: 0.016